Form 4: Saba Capital Management Increases Stake in abrdn Life Sciences Investors (HQL)

Saba Capital Management, a 10% owner and director in abrdn Life Sciences Investors (HQL), acquired 1,303 shares of common stock at $13.50 per share on May 23, 2024, increasing their indirect holdings to 3,251,883 shares.

Summary

• On May 23, 2024, Saba Capital Management, L.P., increased its holdings in abrdn Life Sciences Investors (HQL) by purchasing 1,303 shares of common stock.
• The shares were acquired at a price of $13.50 per share.
• Following this transaction, Saba Capital Management's indirect beneficial ownership in HQL amounts to 3,251,883 shares.
• Boaz Weinstein, a director, is associated with Saba Capital Management.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock transaction. It doesn't inherently convey positive or negative sentiment, but rather reports a factual event.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) trade in their company's stock. This filing indicates a change in ownership by a significant shareholder.

Key Dates